Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

The thyroid and the skeleton

Murphy, Elaine, Williams, Graham R.·2004·Clinical Endocrinology

Abstract

The relationship between the thyroid and the skeleton was first suggested in 1891 when Von Recklinghausen (1891) reported a patient with hyperthyroidism and multiple fractures. Thyroid disease is common; more than 1% of British women receive thyroxine treatment, increasing to over 3% in those over 50 years of age, and the concern is that patients with a history of hyperthyroidism or those receiving thyroxine treatment may be at increased risk of osteoporosis and fractures (Parle et al., 1993). While the clinical consequences of overt hyperthyroidism on bone have been known for many years the molecular mechanism of action of thyroid hormone on bone has remained incompletely understood. Furthermore, earlier recognition of thyroid disease and effective treatment for clinical symptoms has meant that severe bone disease is now uncommonly seen. It is only in more recent years, with the development of more sensitive TSH assays and the recognition that even so-called subclinical thyroid disease, associated with a suppressed TSH but normal FT4 and FT3 levels, may have effects on fracture risk that there has been a renewed interest in the role of thyroid hormone in bone (Klee & Hay, 1988; Bauer et al., 2001). The molecular actions of thyroid hormone in bone have recently been comprehensively reviewed (Harvey et al., 2002; Bassett & Williams, 2003). This review will therefore only briefly summarize this information and instead concentrate in detail on some of the clinical aspects of thyroid hormone effects on bone growth and development in childhood and bone turnover and maintenance in adults. Tables are used to illustrate the effects of thyroid hormone suppressive therapy for thyroid cancer and thyroid hormone replacement on bone mineral density (BMD), and the effects of thyroid hormone on fracture risk. Each clinical section concludes with a summary of the salient points discussed. The role of calcitonin, a hormone also synthesized and secreted by the thyroid gland, and its effects on bone has recently been reviewed and will not be discussed further here (Inzerillo et al., 2002). In adults, the mechanical integrity of the skeleton is maintained by bone remodelling, which results from the localized removal of old bone and its replacement with newly formed bone (Ng et al., 1997). Remodelling enables bone to adapt to mechanical stress and to repair micro-damage, thus maintaining its strength. Alterations in bone remodelling are responsible for most metabolic bone diseases, including osteoporosis and the reduction in BMD seen with uncontrolled hyperthyroidism. Osteoporosis is defined as a BMD value 2·5SDs or more below the mean value for young adults (T score ≤−2·5) (Anonymous, 1991). As well as low bone mass, osteoporosis is characterized by microarchitectural deterioration of bone, with a consequent increase in bone fragility. The major end point of osteoporosis is fracture, especially of the distal forearm, vertebrae or hip, with a two- to threefold increase in fracture incidence for each SD reduction in BMD. It is not clear what initiates remodelling at a particular site on bone but it may be in response to paracrine factors secreted by osteocytes when subjected to mechanical stimuli. During the initial 'activation' phase, interactions between osteoblast (bone-forming) and osteoclast (bone-resorbing) precursors leads to the differentiation, migration and fusion of large multinucleated osteoclasts. Activated osteoclasts adhere closely to the mineralized bone surface. They then secrete hydrogen ions through a proton pump system, and digestive lysosomal enzymes that dissolve the protein matrix of bone at a low pH. Once resorption is complete, osteoclasts undergo programmed cell death (apoptosis) during the 'reversal' phase. Once a certain resorption depth is achieved, the final 'formation' phase begins. Osteoblasts invade the area, lay down new matrix and begin mineralization. The activities of the two cell types, osteoclasts and osteoblasts, are thus tightly coupled. The activation–resorption–formation sequence normally lasts about 200 days. However, when there is either enhanced osteoclastic activity or decreased osteoblastic activity each resorption cavity is only partially filled, resulting in net bone loss. Reconstruction of the bone remodelling sequence in uncontrolled hyperthyroid patients indicates that the duration of remodelling is significantly reduced with a negative balance between resorption and formation, resulting in a net loss of about 10% of mineralized bone per cycle, with ultimately a reduction in BMD and a predisposition to fractures (Eriksen et al., 1985). Calcium kinetic studies in hyperthyroid patients have shown that intestinal calcium and phosphate absorption is reduced, while urinary, faecal and dermal calcium excretion is increased (Mosekilde et al., 1990). Thus thyrotoxicosis is a condition of negative calcium balance and this negative balance may also contribute to the increased fracture r

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2004.02053.x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 158

Metadata

Authors
Murphy, E., & Williams, G. R.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2004-09
Volume
61
Issue
3
Pages
285-298
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2037327864
Cited by
158
References
19
FWCI
4.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The thyroid and the skeleton. https://app.cochat.ai/papers/10.1111/j.1365-2265.2004.02053.x
The paper
Murphy, E., & Williams, G. R. (2004). The thyroid and the skeleton. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2004.02053.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.